KKR may be making the largest ever private equity investment in the Indian subcontinent's health care sector.
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.
After a red-hot start, biotech IPOs are now underperforming the broader market.
Ariad Pharmaceuticals (ARIA) is up, up, and away, after good news on Friday had the stock extending its rally through to Monday.
Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.
Optina's 505(b)(2) filing strategy appears to be running into trouble with the FDA, according to Ampio's SEC filings.
Contrave will be resubmitted for FDA approval "within a few weeks," Orexigen said.
Biogen Idec and Gilead Sciences are helping the biotech sector recover from a sloppy fourth quarter performance.
Novartis (NVS) shares received a shot in the arm after management detailed a $5 billion share repurchase program.
European regulators decide Tecfidera is a "new active substance," clearing way for Biogen to begin selling the multiple sclerosis drug.
European regulators place new patient restrictions on Iclusig but Ariad can continue to sell the drug.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.
Amicus loses ground to rivals Sanofi and BioMarin in the race to develop drugs for rare, orphan diseases.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV